Emergent Biosolutions (EBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 742,900 | 1,043,600 | 1,049,300 | 1,117,500 | 1,773,600 |
| Cost of Goods | 326,200 | 681,300 | 705,400 | 693,100 | 748,100 |
| Gross Profit | 416,700 | 362,300 | 343,900 | 424,400 | 1,025,500 |
| Operating Expenses | 316,800 | 471,300 | 1,070,700 | 594,500 | 684,200 |
| Operating Income | 100,100 | -108,700 | -726,400 | -170,000 | 341,400 |
| Interest Expense | 59,300 | 71,000 | 87,900 | 37,300 | 34,500 |
| Other Income | 42,000 | 36,800 | 83,100 | -11,700 | -3,700 |
| Pre-tax Income | 82,800 | -142,900 | -731,200 | -219,000 | 303,200 |
| Income Tax | 30,200 | 47,700 | 29,300 | -7,400 | 83,700 |
| Net Income Continuous | 52,600 | -190,600 | -760,500 | -211,600 | 219,500 |
| Net Income | $52,600 | $-190,600 | $-760,500 | $-211,600 | $219,500 |
| EPS Basic Total Ops | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
| EPS Basic Continuous Ops | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
| EPS Diluted Total Ops | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 |
| EPS Diluted Continuous Ops | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 |
| EPS Diluted Before Non-Recurring Items | 1.53 | -0.23 | -6.23 | -2.23 | 6.02 |
| EBITDA(a) | $205,700 | $7,500 | $-361,800 | $-15,900 | $511,000 |